2675-35-6

Upstream product

• 611-99-4 4,4'-Dihydroxybenzophenone 
• 119-26-6 (2,4-dinitro-phenyl)-hydrazine 

Downstream Products

• 1033827-21-2 tert-butoxycarbonylamino-acetic acid 4-{[4-(2-tert-butoxycarbonylamino-acetoxy)-phenyl]-[(2,4-dinitro-phenyl)-hydrazono]-methyl}-phenyl ester 
• 1033827-37-0 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone bis(2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside) 
• 1033827-24-5 ethyl {4-([(2,4-dinitrophenyl)hydrazono]-(4-ethoxycarbonyl-methoxyphenyl)-methyl)-phenoxy}-ethanoate 

Relevant academic research and scientific papers

Electrospray-ionization mass spectrometry study of cyclodextrin complexes with A007 prodrugs

Electrospray-ionization mass spectrometric (ESIMS) studies of several A007 prodrugs in aqueous cyclomaltohexaose (α-cyclodextrin, α-CD), cyclomaltoheptaose (β-cyclodextrin, β-CD), and cyclomaltooctaose (γ-cyclodextrin, γ-CD) were performed. The acetic aci

Design, synthesis, and anticancer properties of 4,4′ -dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues

4,4′-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) has recently completed a phase I clinical trial in advanced cancer with minimal toxicity, and impressive objective responses were noted. A-007 possesses three moieties that appear to have an influence on its anticancer activities: diphenylmethane, hydrazone, and dinitrophenyl. The goals of this study were to modify A-007's chemical moieties with the ultimate goal of maximizing its anticancer activity through increased planarity and introduction of functional groups. Thirty-five phenylhydrazone analogues of A-007 were synthesized and evaluated in vitro in a human primary cancer explant assay. Anticancer activities for selected analogues were also assayed for activity vs established human/murine cell lines. One-hundred-eighty-six fresh human solid tumors were used to screen for anticancer activity. Selected analogues were assayed for therapeutic indices (vs GM-CFC from bone marrow) in preparation for preclinical studies. Several polyaryl phenylhydrazones demonstrated improved cytotoxic activities by factors of 102-103 when compared with A-007. However, the polyaryl quinone moieties of the latter analogues introduced potential toxic properties (cardiac, hematological) that do not exist with A-007.